After Losing 17% in the Past Year, Century Therapeutics, Inc. (NASDAQ:IPSC) Institutional Owners Must Be Relieved by the Recent Gain
Century Therapeutics (IPSC) Moves to Buy: Rationale Behind the Upgrade
Century Therapeutics(IPSC.US) Officer Sells US$14,178.5 in Common Stock
$Century Therapeutics(IPSC.US)$ Officer Russotti Gregory sold 5,000 shares of common stock on Jun 20, 2024 at an average price of $2.8357 for a total value of $14,178.5.Source: Announcement What is st
Express News | Century Therapeutics Files For Shelf Of Up To 7.9M Shares Of Common Stock By Selling Stockholders
Express News | Century Therapeutics Inc Files for Shelf of up to 7.9 Mln Shares of Common Stock by Selling Stockholders - SEC Filing
Century Therapeutics Is Maintained at Overweight by Piper Sandler
Century Therapeutics Is Maintained at Overweight by Piper Sandler
Piper Sandler Maintains Century Therapeutics(IPSC.US) With Buy Rating, Raises Target Price to $12
Piper Sandler analyst Edward Tenthoff maintains $Century Therapeutics(IPSC.US)$ with a buy rating, and adjusts the target price from $9 to $12.According to TipRanks data, the analyst has a success rat
Express News | Century Therapeutics Inc : Piper Sandler Raises Target Price to $12 From $9
Century Therapeutics(IPSC.US) Officer Sells US$14,989 in Common Stock
$Century Therapeutics(IPSC.US)$ Officer Russotti Gregory sold 5,000 shares of common stock on Jun 5, 2024 at an average price of $2.9978 for a total value of $14,989.Source: Announcement What is state
5 Analysts Assess Century Therapeutics: What You Need To Know
Across the recent three months, 5 analysts have shared their insights on Century Therapeutics (NASDAQ:IPSC), expressing a variety of opinions spanning from bullish to bearish.In the table below, you'l
Century Therapeutics Price Target Maintained With a $11.00/Share by HC Wainwright & Co.
Century Therapeutics Price Target Maintained With a $11.00/Share by HC Wainwright & Co.
Express News | HC Wainwright & Co. Reiterates Buy on Century Therapeutics, Maintains $11 Price Target
Century Therapeutics Presents Interim Results From Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting
In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting Encouraging preliminary efficacy in heavily
Century Therapeutics(IPSC.US) Officer Sells US$14,977.5 in Common Stock
$Century Therapeutics(IPSC.US)$ Officer Russotti Gregory sold 5,000 shares of common stock on May 20, 2024 at an average price of $2.9955 for a total value of $14,977.5.Source: Announcement What is st
Buy Rating Affirmed for Century Therapeutics on Promising CNTY-101 Prospects and Strong Financial Footing
Express News | Century Therapeutics Inc Files for Shelf of up to 15.9 Mln Shares of Common Stock by Selling Stockholders - SEC Filing
Express News | Century Therapeutics Inc : Guggenheim Cuts Target Price to $12 From $14
Century Therapeutics Inc (IPSC) Q1 2024 Earnings: Aligns With EPS Projections Amid Strategic ...
Century Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Century Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | Century Therapeutics Presents Preclinical Data Highlighting Advances In IPSC Platform Technology And Programs At 2024 ASGCT Annual Meeting